Literature DB >> 31659645

Predictors of Anastomotic Failure After Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy: Does Technique Matter?

Jason T Wiseman1, Charles Kimbrough1, Eliza W Beal1, Mohammad Y Zaidi2, Charles A Staley2, Travis Grotz3, Jennifer Leiting3, Keith Fournier4, Andrew J Lee4, Sean Dineen5, Benjamin Powers5, Jula Veerapong6, Joel M Baumgartner6, Callisia Clarke7, Sameer H Patel8, Vikrom Dhar8, Ryan J Hendrix9, Laura Lambert10, Daniel E Abbott11, Courtney Pokrzywa11, Mustafa Raoof12, Byrne Lee12, Nadege Fackche13, Jonathan Greer13, Timothy M Pawlik1, Sherif Abdel-Misih1, Jordan M Cloyd14.   

Abstract

BACKGROUND: Anastomotic failure (AF) after cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) remains a dreaded complication. Whether specific factors, including anastomotic technique, are associated with AF is poorly understood.
METHODS: Patients who underwent CRS-HIPEC including at least one bowel resection between 2000 and 2017 from 12 academic institutions were reviewed to determine factors associated with AF (anastomotic leak or enteric fistula).
RESULTS: Among 1020 patients who met the inclusion criteria, the median age was 55 years, 43.9% were male, and the most common histology was appendiceal neoplasm (62.3%). The median Peritoneal Cancer Index was 14, and 93.2% of the patients underwent CC0/1 resection. Overall, 82 of the patients (8%) experienced an AF, whereas 938 (92.0%) did not. In the multivariable analysis, the factors associated with AF included male gender (odds ratio [OR], 2.2; p < 0.01), left-sided colorectal resection (OR 10.0; p = 0.03), and preoperative albumin (OR 1.8 per g/dL; p = 0.02).Technical factors such as method (stapled vs hand-sewn), timing of anastomosis, and chemotherapy regimen used were not associated with AF (all p > 0.05). Anastomotic failure was associated with longer hospital stay (23 vs 10 days; p < 0.01), higher complication rate (90% vs 59%; p < 0.01), higher reoperation rate (41% vs 9%; p < 0.01), more 30-day readmissions (59% vs 22%; p < 0.01), greater 30-day mortality (9% vs 1%; p < 0.01), and greater 90-day mortality (16% vs 8%; p = 0.02) as well as shorter median overall survival (25.6 vs 66.0 months; p < 0.01).
CONCLUSIONS: Among patients undergoing CRS-HIPEC, AF is independently associated with postoperative morbidity and worse long-term outcomes. Because patient- and tumor-related, but not technical, factors are associated with AF, operative technique may be individualized based on patient considerations and surgeon preference.

Entities:  

Year:  2019        PMID: 31659645     DOI: 10.1245/s10434-019-07964-x

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  5 in total

Review 1.  Oxaliplatin versus mitomycin C in HIPEC for peritoneal metastasis from colorectal cancer: a systematic review and meta-analysis of comparative studies.

Authors:  Xubing Zhang; Qingbin Wu; Mingtian Wei; Xiangbing Deng; Chaoyang Gu; Ziqiang Wang
Journal:  Int J Colorectal Dis       Date:  2020-07-28       Impact factor: 2.571

2.  Bowel Anastomosis After or Before HIPEC: A Comparative Study in Patients Undergoing CRS+HIPEC for Peritoneal Surface Malignancy.

Authors:  S P Somashekhar; Kumar C Rohit; Yethadka Ramya; Shabber S Zaveri; Vijay Ahuja; Arun Kumar Namachivayam; K R Ashwin
Journal:  Ann Surg Oncol       Date:  2021-08-30       Impact factor: 5.344

3.  Do Lymph Node Metastases Matter in Appendiceal Cancer with Peritoneal Carcinomatosis? A US HIPEC Collaborative Study.

Authors:  Kevin M Turner; Mackenzie C Morris; Aaron M Delman; Dennis Hanseman; Fabian M Johnston; Jonathan Greer; Kara Vande Walle; Daniel E Abbott; Mustafa Raoof; Travis E Grotz; Keith Fournier; Sean Dineen; Jula Veerapong; Ugwuji Maduekwe; Anai Kothari; Charles A Staley; Shishir K Maithel; Laura A Lambert; Alex C Kim; Jordan M Cloyd; Gregory C Wilson; Jeffrey J Sussman; Syed A Ahmad; Sameer H Patel
Journal:  J Gastrointest Surg       Date:  2022-10-18       Impact factor: 3.267

4.  Liver metastasectomy-cytoreductive surgery- hyperthermic intraperitoneal chemotherapy and ileal pouch-anal anastomosis: A case report.

Authors:  Leonidas Chardalias; Antonios Gklavas; Ira Sotirova; Erasmia Vlachou; John Kontis; Ioannis Papaconstantinou
Journal:  Int J Surg Case Rep       Date:  2020-06-13

5.  In-Hospital Mortality and Complication Rates According to Health Insurance Data in Patients Undergoing Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Surface Malignancies in Germany.

Authors:  Lisa Überrück; Giorgi Nadiradze; Can Yurttas; Alfred Königsrainer; Ingmar Königsrainer; Philipp Horvath
Journal:  Ann Surg Oncol       Date:  2020-11-09       Impact factor: 5.344

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.